Increased expression of MCL-1 is a common response to long-term treatment with selective inhibitors of BCL-2/BCL-XL [41].Therefore, available evidences indicate that MCL-1 is an attractive target for cancer treatment. The gene discussed is BCL2L1; the disease is cancer.